Thanks those are my thoughts exactly on the matter. If you know you have the goods why partner prior to the abuse liability and in vitro studies are in hand. Wouldn't make sense to anyone involved.
I was just thinking about Purdue possibly out maneuvering Zogenix on a ADT version of Zohydro. Zogenix has a statement on their website that they intend to develop a ADT Zohyrdo but I'm uncertain what ADT technology they will be using? I may put a call into IR over there later on in the week. I'm curious. I know they partnered with Mallinckrodt on a previous product and Mallinckrodt has spent millions on their ADT technology. They could easily strike up a deal with Mallinckrodt. License their tech.....that is where my idea of Elite licensing their technology came from recently.
Elite has licensed its IP rights in the past to Celgene. Big mistake as Elite got a pittance for it and it makes Celgene and Novartis loads of cash. Elite won't be so foolish this time around IMO.
News 
Market Data 
Discover 
AI
